Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 65 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCCCompletedNCT04124991Phase 1/2
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerCompletedNCT04124601Phase 2
• Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyCompletedNCT04123925Phase 2
• Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04123379Phase 2
• Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2
• Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric CancerStatus unknownNCT04119622Phase 2
• A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal CancerStatus unknownNCT04118933Phase 2
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaCompletedNCT04118855Phase 2
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerActive, not recruitingNCT04117087Phase 1
• Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.Status unknownNCT04116775Phase 2
• CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)Active, not recruitingNCT04116047Phase 3
• Diadem to Investigate the Activity and Safety of DurvalumabCompletedNCT04115111Phase 2
• Study of ADG116 in Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04111445Phase 1
• Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerStatus unknownNCT04110093Phase 1/2
• Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal CancerTerminatedNCT04108481Phase 1
• Immunotherapy in Patient With Poor General ConditionCompletedNCT04108026Phase 2
• A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLCStatus unknownNCT04108013Phase 2
• Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell CarcinomaCompletedNCT04107103Phase 2
• Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentActive, not recruitingNCT04106414Phase 2
• SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLCStatus unknownNCT04106180Phase 2
• A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)CompletedNCT04105335Phase 1
• A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationActive, not recruitingNCT04104893Phase 2
• A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesCompletedNCT04104672Phase 1
• Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor ThrombosisStatus unknownNCT04104074Phase 1
• Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial CarcinomaStatus unknownNCT04099589Phase 2
• PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04098796Phase 2
• STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedNCT04098432Phase 1/2
• The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced MalignanciesCompletedNCT04097769Phase 1
• Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical CancerStatus unknownNCT04096911Phase 2
• Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
• Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugCompletedNCT04095273Phase 1
• Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II StudyCompletedNCT04095208Phase 2
• Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerActive, not recruitingNCT04093167Phase 2/3
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• Treatment of PD-1 Inhibitor in AIDS-associated PMLStatus unknownNCT04091932Phase 2
• Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)CompletedNCT04091490Phase 2
• A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2
• Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy RegimensStatus unknownNCT04089657Phase 2
• Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1
• Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid TumorsCompletedNCT04087018Phase 1
• Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Phase 3
• Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyActive, not recruitingNCT04085250Phase 2
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsStatus unknownNCT04085185Phase 1
• A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.SuspendedNCT04084158Phase 2
• ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationActive, not recruitingNCT04082897Phase 2
• Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingNCT04080804Phase 2
• Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsCompletedNCT04079062Phase 1
• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingNCT04074096Phase 2
• TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder CancerWithdrawnNCT04073160Phase 1
• A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownNCT04072900Phase 1
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Phase 1
• Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsCompletedNCT04072198Phase 2
• EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
• Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor ThrombusStatus unknownNCT04069949Phase 1/2
• Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCTerminatedNCT04069936Phase 2
• Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian CancerStatus unknownNCT04068974Phase 2
• Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingNCT04068753Phase 2
• Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal CancerStatus unknownNCT04067986Phase 1/2
• Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's LymphomaActive, not recruitingNCT04067037Phase 2
• Sintilimab to Prevent High-risk Oral Premalignant Lesions CancerizationStatus unknownNCT04065737Phase 2
• The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Status unknownNCT04065282Phase 2
• ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
• Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLCStatus unknownNCT04063449Not applicable
• Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGActive, not recruitingNCT04062656Phase 2
• Toripalimab With Preoperative Chemoradiotherapy for LA-EGJStatus unknownNCT04061928Phase 1/2
• Nivolumab and Eribulin in HER2 Negative Metastatic Breast CancerStatus unknownNCT04061863Phase 1/2
• Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung CancerWithdrawnNCT04061590Phase 2
• Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]CompletedNCT04059887Phase 4
• Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic CancerWithdrawnNCT04058964Phase 2
• Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study TreatmentsActive, not recruitingNCT04058756Phase 1
• Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyStatus unknownNCT04056949Phase 2
• Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLCCompletedNCT04055792Phase 2
• Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04054518Phase 2
• Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2
• SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedNCT04050085Phase 1
• A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsCompletedNCT04047290Phase 1
• Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass NodulesCompletedNCT04047186Phase 2
• Camrelizumab Combined With Apatinib for Recurrent Resistant GTNCompletedNCT04047017Phase 2
• Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of AnusActive, not recruitingNCT04046133Phase 1
• Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral TherapyWithdrawnNCT04046107Phase 1/2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
• Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Phase 2/3
• Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
• Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawnNCT04044378Phase 1/2
• HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Phase 2
• A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard ChemotherapyStatus unknownNCT04044222Phase 3
• Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCActive, not recruitingNCT04043195Phase 1/2
• Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Phase 2
• Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 2
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• SBRT as a Vaccination for Metastatic MelanomaWithdrawnNCT04042506Phase 2
• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedNCT04042116Phase 1/2
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedNCT04040231Phase 1
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3
• Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver TransplantStatus unknownNCT04035876Phase 1/2

← Immune Checkpoint Inhibitors overview